Skip to content

A Study on the Prevention and Treatment of Mild and Moderate Alzheimer's Disease from the Perspective of Phlegm and Deficiency

A Study on the Prevention and Treatment of Mild and Moderate Alzheimer's Disease from the Perspective of Phlegm and Deficiency

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003780
Enrollment
Unknown
Registered
2020-08-27
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. According to the diagnostic criteria of Western medicine and traditional Chinese medicine for Alzheimer's disease; 2. TCM syndrome differentiation belongs to turbid phlegm type; 3. Patients with mild to moderate Alzheimer's disease were selected by clinical dementia rating scale, Montreal cognitive assessment scale and mini mental state examination scale; 4. The age ranged from 45 to 80 years old, both male and female; 5. Patients or their family members voluntarily participated in the study with informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe neurological impairment, such as hemiplegia, aphasia and visual and hearing impairment; 2. Patients with cognitive impairment caused by other system diseases, such as severe circulatory system, digestive system, urinary system, endocrine system and other diseases; 3. Patients with underlying diseases that affect the oral administration, absorption and metabolism of drugs; 4. Patients with adverse habits, such as alcoholics, drug addicts, psychotropic substance abusers and antidepressants, were included in the study; 5. Patients with serious life-threatening primary diseases and psychosis were found; 6. Allergic constitution; 7. Taking other traditional Chinese medicine or Chinese patent medicine to improve cognition; 8. Patients who participated in other clinical trials within the last 3 months.

Design outcomes

Primary

MeasureTime frame
Time of taking Chinese Medicine;

Secondary

MeasureTime frame
MoCA;MMSE;CDR;ADL;ADAS-cog;TCM Symptom Score Scale;

Countries

China

Contacts

Public ContactZhengyu Lu

Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

lu_zhengyu@163.com+86 18121200096

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026